Published in Kidney Int on January 18, 2012
Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease. Kidney Int (2013) 2.48
The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol (2015) 2.09
Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. PLoS One (2012) 1.90
Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol (2014) 1.24
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One (2013) 1.12
NGAL-Siderocalin in kidney disease. Biochim Biophys Acta (2012) 0.92
Molecular phenotyping of clinical AKI with novel urinary biomarkers. Am J Physiol Renal Physiol (2015) 0.89
Urinary biomarkers at early ADPKD disease stage. PLoS One (2015) 0.87
Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients. BMC Nephrol (2015) 0.85
Urinary N-acetyl-β-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort study. BMC Nephrol (2012) 0.84
A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol (2015) 0.84
Exploring urinary biomarkers in autosomal dominant polycystic kidney disease. Clin Exp Nephrol (2014) 0.78
Biomimetic Cross-Reactive Sensor Arrays: Prospects in Biodiagnostics. RSC Adv (2016) 0.75
Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol (2015) 0.75
Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring. Clin Proteomics (2016) 0.75
Urinary angiotensinogen can be useful for screening patients with polycystic kidney disease. Kidney Int (2014) 0.75
Transcriptome analysis reveals manifold mechanisms of cyst development in ADPKD. Hum Genomics (2016) 0.75
Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus. Can J Kidney Health Dis (2017) 0.75
Diagnostic Value of Urine Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 for Acute Kidney Injury: A Meta-Analysis. PLoS One (2017) 0.75
Urinary biomarkers in autosomal dominant polycystic kidney disease: is there no prognostic value? Kidney Int (2012) 0.75
Autosomal dominant polycystic kidney disease: recent advances in clinical management. F1000Res (2016) 0.75
Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases. Exp Biol Med (Maywood) (2016) 0.75
Urine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression. J Transl Med (2015) 0.75
Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet (2005) 13.77
Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol (2003) 9.08
Autosomal dominant polycystic kidney disease. Lancet (2007) 8.55
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis (2009) 6.99
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int (2007) 4.74
A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med (2007) 4.40
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med (2010) 4.36
Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int (2006) 3.96
Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell (1998) 3.84
Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol (2005) 3.38
An iron delivery pathway mediated by a lipocalin. Mol Cell (2002) 3.38
Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis (2004) 3.35
Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5. Gene (1989) 3.00
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest (2002) 2.65
Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int (2007) 2.64
The ion channel polycystin-2 is required for left-right axis determination in mice. Curr Biol (2002) 2.36
Cardiac defects and renal failure in mice with targeted mutations in Pkd2. Nat Genet (2000) 2.24
Primary cilia and signaling pathways in mammalian development, health and disease. Nephron Physiol (2009) 2.09
Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am J Nephrol (2007) 1.83
Molecular advances in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis (2010) 1.77
Kidney injury molecule-1 expression in murine polycystic kidney disease. Am J Physiol Renal Physiol (2002) 1.64
Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2003) 1.46
Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol (2007) 1.35
Caspases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis. Am J Physiol Renal Physiol (2006) 1.18
Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant (2009) 1.16
Evidence of extraordinary growth in the progressive enlargement of renal cysts. Clin J Am Soc Nephrol (2010) 1.16
Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int (2009) 1.12
Apoptosis in polycystic kidney disease. Biochim Biophys Acta (2011) 1.10
New insights into ADPKD molecular pathways using combination of SAGE and microarray technologies. Genomics (2004) 0.99
Transcriptome analysis of a rat PKD model: Importance of genes involved in extracellular matrix metabolism. Kidney Int (2006) 0.93
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2014) 5.01
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Two populations of node monocilia initiate left-right asymmetry in the mouse. Cell (2003) 4.73
Kidney-specific inactivation of the KIF3A subunit of kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease. Proc Natl Acad Sci U S A (2003) 4.47
Polycystin-2 is an intracellular calcium release channel. Nat Cell Biol (2002) 4.37
Quality of care for children in commercial and Medicaid managed care. JAMA (2003) 3.60
Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol (2011) 3.53
Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol (2002) 3.52
Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol (2005) 3.38
Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis (2004) 3.35
Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. J Am Soc Nephrol (2002) 3.28
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 3.26
PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet (2002) 3.21
A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. Nat Genet (2011) 3.18
Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia. Hum Mol Genet (2008) 3.14
Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med (2004) 3.09
Microarray-based analysis of stress-regulated microRNAs in Arabidopsis thaliana. RNA (2008) 3.09
Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int (2011) 3.05
Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery. J Am Soc Nephrol (2011) 2.90
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension (2012) 2.86
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Polycystin-2 traffics to cilia independently of polycystin-1 by using an N-terminal RVxP motif. J Cell Sci (2006) 2.72
Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease. Nat Genet (2013) 2.71
Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol (2004) 2.69
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest (2002) 2.65
Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int (2004) 2.55
Relationship between staff perceptions of hospital norms and hospital-level end-of-life treatment intensity. J Palliat Med (2007) 2.39
Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J (2008) 2.38
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
DCDC2 is associated with reading disability and modulates neuronal development in the brain. Proc Natl Acad Sci U S A (2005) 2.35
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int (2003) 2.32
Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem (2004) 2.26
Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet (2008) 2.23
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2006) 2.21
Loss of oriented cell division does not initiate cyst formation. J Am Soc Nephrol (2009) 2.20
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J (2009) 2.12
Perceived discrimination in health care and health status in a racially diverse sample. Med Care (2008) 2.06
Mediators of inflammation in acute kidney injury. Mediators Inflamm (2010) 2.05
Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J Clin Invest (2004) 2.00
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens (2010) 1.90
Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol (2003) 1.89
Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther (2007) 1.88
Acute renal failure after bilateral nephrectomy is associated with cytokine-mediated pulmonary injury. J Am Soc Nephrol (2006) 1.88
Molecular advances in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis (2010) 1.77
Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci U S A (2007) 1.75
Increased postoperative and respiratory complications in patients with congenital heart disease associated with heterotaxy. J Thorac Cardiovasc Surg (2010) 1.74
Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA (2012) 1.72
Altered trafficking and stability of polycystins underlie polycystic kidney disease. J Clin Invest (2014) 1.71
Home screening for sexually transmitted diseases in high-risk young women: randomised controlled trial. Sex Transm Infect (2007) 1.70
Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1). J Am Soc Nephrol (2003) 1.70
Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A (2011) 1.69
T-cell factor/β-catenin activity is suppressed in two different models of autosomal dominant polycystic kidney disease. Kidney Int (2011) 1.69
Mutation of hepatocyte nuclear factor-1beta inhibits Pkhd1 gene expression and produces renal cysts in mice. J Clin Invest (2004) 1.67
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension (2008) 1.66
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res (2012) 1.65
Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med (2014) 1.64
Kidney injury molecule-1 expression in murine polycystic kidney disease. Am J Physiol Renal Physiol (2002) 1.64
Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting of urine. Kidney Int (2011) 1.64
Recurrent pain, emotional distress, and health service use in childhood. J Pediatr (2002) 1.64
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol (2011) 1.63
Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol (2010) 1.63
Serum interleukin-6 and interleukin-8 are early biomarkers of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study. Crit Care (2009) 1.61
Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail (2006) 1.61
Calcium dependence of polycystin-2 channel activity is modulated by phosphorylation at Ser812. J Biol Chem (2004) 1.60
Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am J Physiol Renal Physiol (2007) 1.59
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension (2012) 1.59
Cystic and inherited kidney diseases. Am J Kidney Dis (2003) 1.59
Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int (2008) 1.58
Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int (2004) 1.57
Alcohol and drug use and related disorders: An underrecognized health issue among adolescents and young adults attending sexually transmitted disease clinics. Sex Transm Dis (2006) 1.57
Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy. Physiol Genomics (2006) 1.57
Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol (2008) 1.56
The medicinal use of water in renal disease. Kidney Int (2013) 1.56
Some biomarkers of acute kidney injury are increased in pre-renal acute injury. Kidney Int (2012) 1.55
Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. Nephrol Dial Transplant (2007) 1.55